Comparative dosimetric evaluation of nanotargeted (188)Re-(DXR)-liposome for internal radiotherapy
| العنوان: | Comparative dosimetric evaluation of nanotargeted (188)Re-(DXR)-liposome for internal radiotherapy |
|---|---|
| المؤلفون: | Te-Wei Lee, Michael G. Stabin, Liang-Cheng Chen, Chih-Hsien Chang, Tsui-Jung Chang, Ya-Jen Chang, Gann Ting, Min-Hua Chen |
| المصدر: | Cancer biotherapyradiopharmaceuticals. 23(6) |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Male, Cancer Research, medicine.medical_treatment, Normal tissue, Mice, Nude, Polyethylene Glycols, Mice, Colon carcinoma, Pharmacokinetics, Ascites, Medicine, Dosimetry, Animals, Nanotechnology, Radiology, Nuclear Medicine and imaging, Doxorubicin, Tissue Distribution, Radionuclide Imaging, Pharmacology, Liposome, Mice, Inbred BALB C, business.industry, Radiotherapy Dosage, General Medicine, Radiation therapy, Rhenium, Oncology, Colonic Neoplasms, medicine.symptom, Radiopharmaceuticals, Nuclear medicine, business, medicine.drug |
| الوصف: | A dosimetric analysis was performed to evaluate nanoliposomes as carriers of radionuclides ((188)Re-liposomes) and radiochemotherapeutic drugs [(188)Re-doxorubicin (DXR)-liposomes] in internal radiotherapy for colon carcinoma, as evaluated in mice.Pharmacokinetic data for (188)Re-N, N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA), (188)Re-liposome, and (188)Re-DXR-liposome were obtained for the estimation of absorbed doses in tumors and normal organs. Two colon carcinoma mouse models were employed: subcutaneous growing solid tumor and malignant ascites pervading tumor models. Radiation-dose estimates for normal tissues and tumors were calculated by using the OLINDA/EXM program. An evaluation of a recommended maximum administered activity (MAA) for the nanotargeted drugs was also made.Mean absorbed doses derived from (188)Re-liposome and (188)Re-DXR-liposome in normal tissues were generally similar to those from (188)Re-BMEDA in intraperitoneal and intravenous administration. Tissue-absorbed dose in the liver was 0.24-0.40 and 0.17-0.26 (mGy/MBq) and in red marrow was 0.033-0.050 and 0.038-0.046 (mGy/MBq), respectively, for (188)Re-liposome and (188)Re-DXR-liposome. Tumor-absorbed doses for the nanotargeted (188)Re-liposome and (188)Re-DXR-liposome were higher than those of (188)Re-BMEDA for both routes of administration (4-26-fold). Dose to red marrow defined the recommended MAA.Our results suggest that radionuclide and chemoradiotherapeutic passive targeting delivery, using nanoliposomes as the carrier, is feasible and promising in systemic-targeted radionuclide therapy. |
| تدمد: | 1557-8852 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49f87a6bf63f010c43d8c92ba0c113fd https://pubmed.ncbi.nlm.nih.gov/19111045 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....49f87a6bf63f010c43d8c92ba0c113fd |
| قاعدة البيانات: | OpenAIRE |
كن أول من يترك تعليقا!